Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03650491
Recruitment Status : Recruiting
First Posted : August 28, 2018
Last Update Posted : February 1, 2021
Sponsor:
Information provided by (Responsible Party):
Fortis Therapeutics, Inc.

Brief Summary:

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma.

The name of the study drug involved in this study is: FOR46 for Injection


Condition or disease Intervention/treatment Phase
Multiple Myeloma Multiple Myeloma in Relapse Multiple Myeloma With Failed Remission Drug: FOR46 Phase 1

Detailed Description:

This study is designed to evaluate the safety, tolerability and antitumor activity of FOR46 in patients with relapsed or refractory multiple myeloma. This study will be conducted in two parts:

Dose escalation:

This part will evaluate increasing doses of FOR46 to identify the maximum tolerated dose (MTD). The first patient enrolled on the study will receive the lowest dose of FOR46. Once this dose is shown to be safe, a second patient will be enrolled at the next higher dose. Patients will continue to be enrolled into either single or multiple patient groups receiving increasing doses until the MTD is reached.

Dose expansion:

This part of the study will further evaluate the safety, tolerability and antitumor activity of FOR46 at a dose shown to be safe in the dose escalation part of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Following completion of the dose escalation phase of the study and determination of a recommended phase 2 dose, patients will be enrolled into a dose expansion cohort.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Actual Study Start Date : April 3, 2019
Estimated Primary Completion Date : March 16, 2021
Estimated Study Completion Date : September 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: Experimental: FOR46 (Dose Escalation)
Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
Drug: FOR46
FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46

Experimental: Experimental: FOR46 (Dose Expansion)
Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
Drug: FOR46
FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46




Primary Outcome Measures :
  1. Incidence of adverse events [ Time Frame: Through 1 month following last dose ]
    Number of patients with treatment-related adverse events as assessed by NCI CTCAE v5.0.

  2. Occurrence of dose-limiting toxicities [ Time Frame: Through 1 month following last dose ]
    The severity and incidence of dose-limiting toxicities related to escalating dose levels of FOR46

  3. Disease response [ Time Frame: 6 months ]
    Overall response rate of FOR46, defined as all responses greater than or equal to a partial response, complete response, stringent complete response, or minimal residual disease negativity


Secondary Outcome Measures :
  1. Characterize FOR46 plasma concentration [ Time Frame: Through 1 month following last dose ]
    FOR46 maximum plasma concentration

  2. Characterize the FOR46 area under the curve [ Time Frame: Through 1 month following last dose ]
    FOR46 area under the plasma concentration-time curve

  3. Characterize FOR46 elimination [ Time Frame: Through 1 month following last dose ]
    FOR46 elimination half-life

  4. Antidrug Antibodies [ Time Frame: Through 1 month following last dose ]
    Change from baseline in serum levels of antidrug antibodies

  5. Duration of response [ Time Frame: From first dose through 6 months following last dose ]
    Assessed by IMWG criteria

  6. Progression-free survival [ Time Frame: From first dose through 6 months following last dose ]
    Assessed by IMWG criteria

  7. Time to progression [ Time Frame: From first dose through 6 months following last dose ]
    Assessed by IMWG criteria



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ≥ 18 years of age
  • Measurable MM that is relapsed or refractory to established therapies with known clinical benefit in RRMM or intolerant of those established MM therapies. Prior lines of therapy must include a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD) and a CD38-directed therapy in any order of combination.
  • ECOG performance status of 0 or 1
  • Adequate hematologic, renal and hepatic function
  • Females of child-bearing potential must have a negative serum pregnancy test and use a medically acceptable form of contraception
  • Male patients with with female partners of childbearing potential must agree to use 2 effective methods of contraception
  • Patients must provide signed informed consent

Exclusion Criteria:

  • Persistent clinically significant toxicities from previous anticancer therapy
  • NCI CTCAE Grade ≥ 2 peripheral neuropathy from any etiology or has a genetic disorder that is associated with peripheral neuropathy even without current neuropathic manifestations
  • Has received treatment with a stem cell transplant within 12 weeks before administration of patient's first dose of FOR46
  • Has had radiation or systemic anticancer therapy within 14 days before first dose of FOR46
  • Has received treatment with an investigational drug within 28 days before first dose of FOR46
  • Has had a major surgical procedure within 28 days before administration of the patient's first FOR46 dose
  • Is breastfeeding
  • Clinically significant cardiovascular disease
  • Uncontrolled, clinically significant pulmonary disease
  • Uncontrolled intercurrent illness
  • Has known positive status for HIV or either active/chronic hepatitis B/C
  • Requires anticoagulation with warfarin or direct thrombin inhibitor; a washout of 7 days before the administration of a patient's first FOR46 dose is required for patients removed from these treatments
  • Requires medications that are strong inhibitors or strong inducers of CYP3A4
  • Has a history of episodic atrial fibrillation or flutter; patients with chronic atrial fibrillation are not excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03650491


Contacts
Layout table for location contacts
Contact: Andrew Dorr, MD 858-504-1453 adorr414@me.com
Contact: Jill Abbey 925-286-0832 jill.abbey@gmail.com

Locations
Layout table for location information
United States, California
UCSF Helen Diller Family Comprehensive Cancer Center Recruiting
San Francisco, California, United States, 94143
Contact: Eseosa Igbinedion    415-502-3550    Eseosa.Igbinedion@ucsf.edu   
Contact: Kate Rafanova    415-502-4751    Kate.Rafanova@ucsf.edu   
Principal Investigator: Sandy Wong, MD         
United States, Colorado
University of Colorado Cancer Center Recruiting
Aurora, Colorado, United States, 80045
Contact: Rachael Wax    720-848-9384    Rachael.Wax@ucdenver.edu   
Contact: Noelle Mahleres    720-848-2409    noelle.mahleres@ucdenver.edu   
Principal Investigator: Tomer Mark, MD         
United States, Georgia
Winship Cancer Institute, Emory University Recruiting
Atlanta, Georgia, United States, 30322
Contact: Shandolyn Richburg       shondolyn.richburg@emoryhealthcare.org   
Principal Investigator: Jonathan Kaufman, MD         
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21231
Contact: Amanda Stevens    443-287-0180    msteve35@jhmi.edu   
Principal Investigator: Phillip Imus, MD         
United States, Michigan
Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Silvia Pregja    313-576-8673    pregjas@karmanos.org   
Principal Investigator: Jeffrey Zonder, MD         
United States, Missouri
Washington University in St. Louis-Siteman Cancer Center Recruiting
Saint Louis, Missouri, United States, 63310
Contact: Dan Feinberg    314-747-3094    feinberg.daniel@wustl.edu   
Principal Investigator: Mark A Schroeder, MD         
United States, New York
Icahn School of Medicine at Mt. Sinai Recruiting
New York, New York, United States, 10029
Contact: Katarzyna Zarychta    212-241-2495    katarzyna.zarychta@mssm.edu   
Principal Investigator: Ajai Chari, MD         
Sponsors and Collaborators
Fortis Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Andrew Dorr, MD Fortis Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Fortis Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03650491    
Other Study ID Numbers: FOR46-002
First Posted: August 28, 2018    Key Record Dates
Last Update Posted: February 1, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases